According to AstraZeneca's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5.01691. At the end of 2023 the company had a P/S ratio of 4.56.
Year | P/S ratio | Change |
---|---|---|
2023 | 4.56 | -3.93% |
2022 | 4.74 | -2.19% |
2021 | 4.85 | -1.45% |
2020 | 4.92 | -8.31% |
2019 | 5.37 | 25.56% |
2018 | 4.27 | 10.21% |
2017 | 3.88 | 29.36% |
2016 | 3.00 | -14.32% |
2015 | 3.50 | 3.59% |
2014 | 3.38 | 17.2% |
2013 | 2.88 | 37.53% |
2012 | 2.10 | 17.67% |
2011 | 1.78 | -8.96% |
2010 | 1.96 | -5.78% |
2009 | 2.08 | 10.47% |
2008 | 1.88 | -10.96% |
2007 | 2.11 | -31.88% |
2006 | 3.10 | -4.92% |
2005 | 3.26 | 16.72% |
2004 | 2.79 | -35.74% |
2003 | 4.35 | 27.15% |
2002 | 3.42 | -1.11% |
2001 | 3.46 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 4.14 | -17.45% | ๐บ๐ธ USA |
Novartis NVS | 4.20 | -16.34% | ๐จ๐ญ Switzerland |
Pfizer PFE | 2.80 | -44.16% | ๐บ๐ธ USA |
Abbott Laboratories ABT | 4.55 | -9.34% | ๐บ๐ธ USA |
Eli Lilly LLY | 20.4 | 306.55% | ๐บ๐ธ USA |
Sanofi SNY | 2.44 | -51.39% | ๐ซ๐ท France |
Biogen BIIB | 3.47 | -30.91% | ๐บ๐ธ USA |
Merck MRK | 5.51 | 9.92% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | 1.96 | -60.86% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | 2.40 | -52.14% | ๐ฌ๐ง UK |